Axsome Therapeutics reports 62% YoY revenue growth in Q1 2025, fueled by Auvelity & Sunosi. Key milestones include Symbravo launch & AXS-14 FDA decision.

Axis Capital Holdings AXS +0.34% + Free Alerts has outperformed the market over the past 5 years by 7.48% on an annualized ...

Reading & Leeds and The Bodega also claimed awards, while Arctic Monkeys frontman Alex Turner presented manager Ian McAndrew ...

Discover what crypto is and how it works. A cryptocurrency is a digital form of money. They are digital assets created to be used to pay for goods and services. Cryptocurrencies can be used as a ...

Specialty drugs are increasingly entering general medicine. Experts at Asembia’s AXS Summit say the trend will put a premium ...

According to a new report, TNA Wrestling has enacted a rule against blading during matches in an effort to cut down on ...

A weeklong AEG promotion for "all-in" $25 concert tickets to shows at the Agora, Jacobs Pavilion and new Globe Iron concert ...

Q1 2025 Earnings Call Transcript May 5, 2025 Operator: Greetings, and welcome to the Axsome Therapeutics First Quarter 2025 ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous ...

The company, owned and operated by veteran wrestler Arik Cannon, has announced its 4th "Saturday Night Nitro" will emanate ...

Rocket Arena will host top concert acts in 2025, including Nine Inch Nails, Eric Clapton, Benson Boone, Ghost, Tate Mcrae, ...